Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 12/2015

01-12-2015 | Microvascular Complications—Nephropathy (T Isakova, Section Editor)

Therapies on the Horizon for Diabetic Kidney Disease

Authors: Sadaf S. Khan, Susan E. Quaggin

Published in: Current Diabetes Reports | Issue 12/2015

Login to get access

Abstract

Diabetic nephropathy is rapidly becoming the major cause of end-stage renal disease and cardiovascular mortality worldwide. Standard of care therapies include strict glycemic control and blockade of the renin-angiotensin-aldosterone axis. While these treatments slow progression of diabetic nephropathy, they do not arrest or reverse it. Newer therapies targeting multiple molecular pathways involved in renal inflammation, fibrosis, and oxidative stress have shown promise in animal models. Subsequently, many of these agents have been investigated in clinical human trials with mixed results. In this review, we will discuss recent findings of novel agents used in the treatment of diabetic nephropathy.
Literature
1.
Tazo Z, Shia A, Zhao J. Epidemiological perspectives of diabetes. Cell Biochem Biophys. 2015.
2.
Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015;66(1 suppl 1):S1–306.
3.
Chawla V, Bijan R. Non-proteinuric Diabetic Nephropathy. Curr Diab Rep. 2014; 14–529.
4.
Messent JW, Elliot TG, Hill RD, et al. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int. 1992;41:836–9.CrossRefPubMed
5.
6.
7.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef
8.
UK Propspective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
9.
National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850–86.CrossRef
10.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.CrossRef
11.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38 suppl 1:S1–93.
12.
Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic enphroatphy. N Engl J Med. 2013;369:1892–903.CrossRefPubMed
13.
Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicenter, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.CrossRefPubMed
14.
Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204–13.CrossRefPubMed
15.
Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64–8.CrossRefPubMed
16.
Rossing K, Schoedt K, Smidt U, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care. 2005;28:2106–211.CrossRefPubMed
17.
Bianchi S, Bigazzi R, Campese V, et al. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005;46:45–51.CrossRefPubMed
18.
Zoja C, Benigni A, Remuzzi G. The Nrf2 pathway in the progression of renal disease. Nephrol Dial Transplant. 2014;29:i19–24.CrossRefPubMed
19.
Aminzadeh MA, Reisman SA, Vziri ND, et al. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuate oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica. 2014;44:570–8.PubMedCentralCrossRefPubMed
20.
Pergola P, Raskin P, Toto P, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011;365:327–36.CrossRefPubMed
21.
Chin M, Reisman S, Bakris G, et al. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes and stage 4 chronic kidney disease treated with Bardoxolone Methyl. Am J Nephrol. 2014;39:499–508.CrossRefPubMed
22.
McCormick B, Sydor A, Akbari A, et al. The effects of pentoxifylline on proteinuria in diabetic kidney diseaes: a meta-analysis. Am J Kidney Dis. 2008;52:454–63.CrossRefPubMed
23.•
Navarro-Gonzalez J, Mora-Fernandez C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol. 2015;26:220–9. In this study, the addition of pentoxifylline to RAS blockade demonstrated reduction in albuminuria and slowed decreased in eGFR.CrossRefPubMed
24.
Perkins RM, Aboudara MC, Uy AL, et al. Effect of pentoxifylline on GFR decline in CKD: A pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2009;53:606–16.CrossRefPubMed
25.
Evcimen ND, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 2007;55:498–510.CrossRefPubMed
26.
Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000;14(3):439–47.PubMed
27.
Tuttle KR, Bakris GL, Toto JB, et al. The effects of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005;28:2686–90.CrossRefPubMed
28.
Gilbert RE, Kim SA, Tuttle GL, et al. Effects of ruboxistuarin on urinary transforming growth factor-b in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care. 2007;30:995–6.CrossRefPubMed
29.
Tuttle KR, McGill JB, Haney DJ, et al. Kidney outcomes in long-term studies of ruboxistuarin for diabetic eye disease. Clin J Am Soc Nephrol. 2007;2:631–6.CrossRefPubMed
30.
Tuttle KR, Bastyr III JB, McGill CL, et al. Albuminuria and kidney function in a long-term study of ruboxistaurin for diabetic neuropathy. J Am Soc Nephrol. 2007;2(4):631–6.CrossRef
31.
Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2:906–13.CrossRefPubMed
32.
33.
Kanamori H, Matsubara T, Mima A, et al. Inhibition of MCP-1/CRR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun. 2007;360:727–7.
34.
Tesch GH. MCP-1/CLL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2008;294:F697–701.CrossRefPubMed
35.
Ruggenenti P, Negarim M. Effects of MCP-1 inhibition by bindarit therapy in type 2 diabetes subjects with micro- or macro- albuminuria. J Am Soc Nephrol. 2010: 21.
36.
Ble A, Mosca M, Loretto GD, et al. Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. Am J Nephrol. 2011;34(4):367–72.CrossRefPubMed
37.
Gambaro G, Cavazzana AO, Luzi P, et al. Glycosasminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int. 1992;42:285–91.CrossRefPubMed
38.
Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int. 1994;46:797–806.CrossRefPubMed
39.•
Ceol M, Nerlich A, Baggio B, et al. Increased glomerular expression α1(IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment. Lab Investig. 1996;74:484–95. In this study, atrasentan (a selective endothelin A receptor antagonist) with RAS inhibition successfully reduced albuminuria in type 2 diabetic nephropathy and thus may improve renal outcomes.PubMed
40.
Ceol M, Gambaro G, Sauer U, et al. Glycosaminoglycan therapy prevents TGF- β 1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol. 2000;11:2324–36.PubMed
41.
Van den Hoven MJ, Rops AL, Bakker MA, et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 2006;70:2100–8.PubMed
42.
Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002;13:1615–25.CrossRefPubMed
43.
Lewis EJ, Lewis JB, Greene T, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011;58:729–36.CrossRefPubMed
44.
Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotective in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23:123–30.PubMedCentralCrossRefPubMed
45.
Wenzel R, Littke T, Kuranoff S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Neprol. 2009;20:655–64.CrossRef
46.
47.
Kohan DE. Addition of atrasetan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;58:763–72.CrossRef
48.
Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2010;35:99–104.CrossRef
49.
Kang DH, Park SK, Lee IK, et al. Uric acid- induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16:3553–62.CrossRefPubMed
50.
Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–9.CrossRefPubMed
51.
Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effects of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–93.PubMedCentralCrossRefPubMed
52.
Maahs DM, Caramori ML, Cherney DZI, et al. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL). Curr Diab Rep. 2013;13(4):550–9.PubMedCentralCrossRefPubMed
53.
Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2012;302:F647–57.CrossRefPubMed
54.
de Zeeuw D, Agrawal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetic nephropathy (VITAL study): a randomised controlled trial. Lancet. 2010;367:1543–51.CrossRef
55.
The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–120.PubMedCentralCrossRef
56.
Koh GY. Orchestral actions of angiopoeitin-1 in vascular regeneration. Trends Mol Med. 2013;19(1):31–9.CrossRefPubMed
57.
58.
Jeansson M, Gawlik A, Anderson G, et al. Angiopoeitin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest. 2011;121(6):2278–89.PubMedCentralCrossRefPubMed
59.
Giacoo F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70.CrossRef
60.
Gray SP, Di Marco E, Okabe J, et al. NADPH oxidase 1 plays a role in diabetes mellitus-accelerated atherosclerosis. Circulation. 2013;127(18):1888–902.CrossRefPubMed
61.
Ortiz-Muñoz, Lopez-Parra V, Lopez-Franco O, et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol. 2010;21(5):763–72.PubMedCentralCrossRefPubMed
62.
Walsh DW, Roxburgh SA, McGettigan P, et al. Co-regulation of Gremlin and Notch signaling in diabetic nephropathy. Biochim Biophys Acta. 2008;1782(1):10–21.CrossRefPubMed
63.
Marrero MB, Banes-Berceli AK, Stern DM, et al. Role of JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol. 2006;290(4):F762–8.CrossRefPubMed
64.
Wang X, Shaw S, Amiri F, et al. Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes. 2002;51(12):3505–9.CrossRefPubMed
Metadata
Title
Therapies on the Horizon for Diabetic Kidney Disease
Authors
Sadaf S. Khan
Susan E. Quaggin
Publication date
01-12-2015
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 12/2015
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-015-0685-3

Other articles of this Issue 12/2015

Current Diabetes Reports 12/2015 Go to the issue

Microvascular Complications—Neuropathy (R Pop-Busui, Section Editor)

Retinal Failure in Diabetes: a Feature of Retinal Sensory Neuropathy

Diabetes Epidemiology (NM Maruthur, Section Editor)

Epidemiology of NAFLD and Type 2 Diabetes: Health Disparities Among Persons of Hispanic Origin

Diabetes Epidemiology (NM Maruthur, Section Editor)

Undiagnosed MODY: Time for Action

Diabetes Epidemiology (NM Maruthur, Section Editor)

Betatrophin in Diabetes Mellitus: the Epidemiological Evidence in Humans

Macrovascular Complications in Diabetes (VR Aroda and A Getaneh, Section Editors)

Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits